The Relationship Between Chemotherapy Related Neutropenia and Survival in Ovarian Cancer

Objectives: Due to limited data in the literature, we aimed to determine the relationship between the development of chemotherapy-induced neutropenia and survival in patients with ovarian cancer who underwent frontline cytoreduc- tive surgery and received adjuvant chemotherapy. Methods: In this study, laboratory parameters in the hospital database were collected retrospectively. The rates of pa- tients who developed neutropenia due to chemotherapy and the relationship between neutropenia and survival were analyzed using appropriate statistical methods. Results: A total of 82 patients were included in the study. The median age was 53.3 years. Median follow-up time was 61,6 months. Median chemotherapy cycles were 6. Disease recurrence developed in 22 (26.8%) patients and 12 pa- tients (14.6%) were died during the follow-up period. Any degree of neutropenia developed in a total of 63 (76.8%) pa- tients during the entire chemotherapy period. There were no grade 4 neutropenia. No correlation was found between the development of neutropenia and disease free survival or overall survial. Conclusion: There are conflicting data in the literature regarding the relationship between chemotherapy-induced neutropenia and survival in patients with ovarian cancer who are receiving adjuvant chemotherapy. In our study, no relationship was found between the development of neutropenia and survival.